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Introduction: Recent studies indicated that supplementation of phosphatidylcholine has been found to be beneficial
for psychiatric diseases and Diacylglycerol Kinase, Eta (DGKH) protein was involved in regulating the metabolism of
phosphatidic acid and diacylglycerol. This study reported a case of a 16-year-old Chinese boy with bipolar hypomania
symptoms receiving supplementation of phosphatidylcholine, and a genetic study of a risk variant of DGKH gene
was performed in an attempt to provide an explanation for the potential beneficial effect of phosphatidylcholine
supplementation.
Case description: We described a case of a 16-year-old boy with bipolar disorder, who suffered from monthly
episodes of insomnia accompanied by hypomania for 5 months despite adherence to medication. After supplementation
of phosphatidylcholine, he returned to a normal sleeping pattern and recovered from hypomania symptoms for
approximately 14 months. Furthermore, genotyping results showed that this boy carries the risk genotype (G/C)
in DGKH variant rs77072822 (adjusted p-value = 0.025 after 2000 permutation tests).
Discussion and evaluation: The 16-year-old boy appears to have benefited from the supplementation with
phosphatidylcholine and recovered from hypomania symptoms. He carries a risk genotype in rs77072822 which
lies in the first intron of DGKH gene that was mostly reported to be associated with bipolar disorder. Thus, this
finding is consistent with the hypothesis that alleviating the phosphatidylcholine deficiencies might accompany
with the risk variants of DGKH gene, which might improve the efficacies of such supplementation and design
new treatment strategies for bipolar disorder.
Conclusions: This study illustrated that a 16-year-old boy with hypomania symptoms responded well to supplementation
of phosphatidylcholine and the boy carries a risk genotype in DGKH gene for bipolar disorder, which provides a
possible explanation for the boy’s beneficial effect at the genetic level.
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The use of phosphatidylcholine has been found to be
beneficial for the neonatal pathophysiology. Recently Ross
et al. had conducted a randomized placebo-controlled
clinical trial with 100 healthy pregnant women using sup-
plementation of phosphatidylcholine (Ross et al. 2013).
They found that the endophenotypes associated with
schizophrenia (i.e. inhibition of the P50 component of the
cerebral evoked response to paired sounds) were dimin-
ished in subjects taking phosphatidylcholine even when
they carry the genetic risk allele for schizophrenia
(CHRNA7 risk allele). Moreover, double-blind placebo-
controlled trials of pure lecithin (in a dose of 10 g three
times a day) in the treatment of mania also demonstrated
improvement of treated compared with placebo in five of
the six patients studied (Cohen et al. 1982). A case report
of a 13-year-old girl with mania symptoms had also been
published with good response to lecithin only while non-
responsive to neuroleptics and lithium (Schreier 1982).
The possible mechanism of the beneficial effect of
phosphatidylcholine supplementation for schizophrenia
or bipolar mania symptoms had been explored by many
studies. For example, the number of manic episodes was
found to be associated with elevated DNA oxidation in
bipolar I disorder (D’Souza et al. 2013). Supplementation
of phosphatidylcholine could lead to better transport of
vitamin E, which overcome the oxidative damage to activ-
ities of the brain (Mesmin and Antonny 2013). Besides,
another hypothesis about the unbalance of metabolism of
diacylglycerol (DAG) and phosphatidic acid (PA) had been
proposed. Since diacylglycerol kinase (DGK) enzymes
phosphorylate DAG into PA when receptors in phosphoi-
nositide pathway receiving activation. DAG is released
from phospholipids such as phosphatidylcholine (Merida
et al. 2008). Both DAG and PA are crucial molecular
regulators of a wide range of biological processes. It
can be speculated that those individuals with deficient
DGK enzymes might not have a balanced DAG and PA,
and supplementation with phosphatidylcholine might
alleviate a deficiency in the substrate level of PA. Thus,
those genes encoding DGK enzymes are likely to play a
key role in the pathogenesis of bipolar mania.
Diacylglycerol kinase eta (DGKH), encoding the type II
DGK enzymes subfamily together with DGK-delta, is
involved in regulating the intracellular concentrations of
DAG and PA. DGKH protein, encoding by DGKH, is
a vital protein involved in the lithium-sensitive phos-
phatidylinositol pathway (Berridge 1989). Moreover, lith-
ium is an effective compound approved by the FDA as a
mood-stabilizing drug in the treatment of bipolar mania
episodes due to the neurological effects of the ion- Li+
in the human body. Therefore, it is believed that DGKH
might be an important candidate gene associated with
bipolar mania symptom based on its biological function.With the advent of genomics research, it is possible to
investigate common genetic variants and see whether
any common variant is associated with bipolar disorder.
In 2008, DGKH was reported to associate with bipolar
disorder in a genome-wide association study and many
polymorphisms located in DGKH were found to be asso-
ciated in a population (of European origin) as reported
by the National Institute of Mental Health or a German
replicate sample (Baum et al. 2008), such as rs9532988,
rs9532989 and rs1012053. Subsequently, Zeng and col-
leagues also confirmed that DGKH was associated with
bipolar disorder in a Chinese Han population including
1139 unrelated bipolar disorder patients and 1138 eth-
nically matched healthy controls using a tagging single
nucleotide polymorphisms (SNPs) strategy (Zeng et al.
2011). In their study, a haplotype block (rs9315885-
rs9532988-rs1012053) was identified as a risk haplotype
(P = 3.87∗10-6, OR = 1.98, 95 % confidence interval =
1.47-2.65). Interestingly, both of the two studies sup-
ported that the first intron of DGKH containing the top
associated polymorphisms or haplotypes is the most sig-
nificantly associated region with bipolar disorder.
Taken together, it is possible that variants in DGKH,
especially in the first intron, would be associated with
the beneficial effect of phosphatidylcholine supplementa-
tion for bipolar mania symptoms. In this study, we re-
ported a bipolar hypomania case of a 16-year-old Chinese
boy who had been alleviated of hypomania and insomnia
symptoms upon supplementation of phosphatidylcholine.
Following this observation, we aimed to investigate
whether the potential beneficial effect of phosphatidyl-
choline supplementation was associated with the fact
that the boy carries susceptibility variants in the first
intron of DGKH for bipolar disorder.
Materials and methods
Diagnosis and treatment of a Chinese boy with bipolar
hypomania
A 16-year-old boy from Hong Kong Shatin district was
diagnosed to suffer from bipolar hypomania symptoms
by an experienced clinical psychiatrist in Prince Wales
of Hospital (Shatin, Hong Kong) with the assistance of
the Chinese-Bilingual Structured Clinical Interview for
DSM-IV (Axis I, Patient version) (CB-SCID-I/P) (Spitzer
et al. 1990), which is a semi-structured face to face inter-
view to access current and lifetime DSM-IV Axis I diag-
nosis. The detailed performance of this boy had been
documented. Despite his adherence to medication, the
boy still experienced monthly episodes of hypomania
and sleeplessness after five months post-discharge from
the hospital (28th May, 2012). As the subject’s parents
felt that their son was already very much sedated and
was gaining a lot of weight with the doses of valproate
and olanzapine prescribed, and that their son is mostly
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(which is well tolerable by the family), they did not wish
to add more mood stabilizer or atypical antipsychotic
medications. The authors chose a patient of 16-year-old
as a clinical case since it was a very interesting case with
a regular monthly episode of hypomania which is not
commonly observed in other bipolar subjects. Since Ross
et al. had conducted a randomized placebo-controlled
clinical trial using supplementation of phosphatidylcho-
line successfully (Ross et al. 2013), the boy was put on a
daily supplement of one capsule of the supplement
(1000 mg) containing the following: phosphatidylcholine
600 mg, Vitamin B1 1 mg, Vitamin B2 1.5 mg, Vitamin
B6 1.5 mg, Vitamin B12 1 μg, folate 15 mg, Vitamin E
18 mg (18 IU) (Super Life Phoschol Revival from MJ Life
Enterprise Co. Ltd. Taiwan) (Growdon and Wurtman
1980; Hirsch 1991; Lieber 1994; Wurtman et al. 1986).
In the month following the supplementation, all of the
boy’s hypomania and insomnia symptoms had disappeared.
Microarray experiment for the Chinese boy and his three
family members
Four DNA samples from the 16-year-old Chinese boy
and his three healthy family members (mother, father
and older sister) were sent to 23andMe to carry out the
detection of SNPs using Illumina HumanOmniExpress-
24 format chip. 23andMe provides laboratory testing in
a CLIA-certified laboratory.
When we focused on the susceptibility region- the first
intron of DGKH in their sequencing data - there is a “noFig. 1 LD Block 2 of the DGKH gene. The graph was generated by Haplovi
downloaded from the HapMap project (Data Phase III/Rel#2, Feb09). The fig
DGKH gene. The SNPs in the red boxes had been identified to be associate
Zeng’s study (haplotype analyses, i.e. rs9315885-rs9532988-rs1012053)call” signal for the boy in rs9532989, whereas all of his
three family members have signal in this SNP (G/G for
his sister and father, G/T for his mother). Thus, we pre-
sumed that rs9532989 or the nearby SNPs in the same
linkage disequilibrium (LD) block with rs9532989 (Fig. 1)
might be associated with the beneficial effect of phos-
phatidylcholine supplementation for the 16-year-old
boy’s hypomania symptoms as these SNPs in the first in-
tron have been associated with bipolar disorder. There-
fore, in this study a region covering rs9532989 and its
nearby SNPs was chosen for sequencing analyses. This
region covers a total of 10 SNPs according to the dbSNP
database. They are rs7990452 (A/T), rs9532987 (A/G),
rs9562372 (C/T), rs17519207 (C/T), rs77072822 (C/G),
rs9532988 (A/G), rs9532989 (G/T), rs79738935 (C/T),
rs4142112 (C/G) and rs4142111 (C/T). All of these SNPs
were genotyped using the dideoxy-sequencing method
after DNA amplification.
DNA extraction and genotyping
Genomic DNA was extracted from two milliliters of
saliva samples of each participant using the OrageneTM
DNA self-collection kit according to the manufacturer’s
instruction (DNA Genotek, Inc., Ottawa, Canada).
After DNA extraction, the concentration of genomic
DNA was determined by Nanodrop 2000c spectropho-
tometer (Thermo Fisher Scientific Inc., MA, US). The
10 SNPs were genotyped using Sanger sequencing in
BGI Company after PCR amplification. Briefly, the tar-
get region was amplified with the forward primer 5′-ew program based on the population of Han Chinese genotype data
ure located in the lower left corner is the LD Block across the whole
d with bipolar disorder in Baum’s study (single marker analyses) or
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primer 5′- TACGCCAATAAAGAATTGAGCTG at a
25 μl volume. For PCR reaction, 200 ng genomic DNA
was amplified using the optimized protocol, in which
the DNA was denatured for 5 min at 95 °C and amplified
over 6 cycles of 10 s at 95 °C, 20 s at 62 °C (decreasing
1 °C for each cycle) and 80 s at 72 °C, followed by 40 cycles
of 10 s at 95 °C, 20 s at 56 °C and 80 s at 72 °C, finally
annealed for 5 min at 72 °C. Genotypes were manually
assigned based on Chromas software (version 2.23).
Subjects for association study
The study sample consisted of 19 bipolar disorder pa-
tients (nine males and ten females, 37.7 ± 13.1 years)
and 17 healthy subject controls (seven males and ten
females, 31.8 ± 10.5 years), which were type I or type II
bipolar disorder subjects recruited from the Shatin
Hospital, Hong Kong. The samples of four members
of the 16-year-old boy’s family were also included in
this study.
They were all Chinese of Han ethnic origin. All sub-
jects were required to conduct the CB-SCID-I/P inter-
view. Bipolar disorder patients suffering from mental
retardation or organic brain syndrome (i.e. dementia)
were excluded. All subjects’ written informed consents
were obtained after a comprehensive and detailed de-
scription of this study. This study was approved by the
Joint Chinese University of Hong Kong–New Territories
East Cluster Clinical Research Ethics Committee.
Statistical analysis
Comparisons of continuous and categorical variables
were accomplished by t test and chi-square test respect-
ively using SPSS program (version 20.0). The genotypic
and allelic frequencies between the bipolar disorder pa-
tients and healthy controls were compared by genotypic
model and allelic model respectively using case–control
association test in UNPHASED program (Dudbridge
2006, 2008). Hardy-Weinberg equilibrium (HWE) tests
were used to examine the genotypic distribution of
SNPs in samples. Linkage disequilibrium (LD) between
SNPs was calculated in Haploview program using r2 al-
gorithm (version 4.2) (Wigginton et al. 2005). LD block
plots of DGKH gene was generated based on the popu-
lation of Han Chinese genotype data downloaded from
the HapMap project (Data Phase III/Rel#2, Feb09). The
association study of 2-marker haplotypes with bipolar
disorder was also performed in Haploview (Barrett
et al. 2005). Moreover, given the possible error pro-
duced by partially dependent SNPs and small sample
size in this study, 2000 permutation tests were used to
run corrections for those preliminary significant tests.
P-values after permutation tests less than 0.05 were
considered statistically significant.Human and animal rights and informed consent
All procedures followed were in accordance with the
ethical standards of the responsible committee on hu-
man experimentation (institutional and national) and
with the Helsinki Declaration of 1975, as revised in 2000
(5). Informed consent was obtained from all patients for
being included in the study.
Results
Hypomania symptoms of a 16-year-old bipolar Chinese
boy
The boy was well until after his 16th birthday. He had a
sudden onset of a hypomania episode precipitated after
a stressful situation at school. On the day of manifestation
of symptoms, he had consumed some alcohol (approxi-
mately 200 ml of rice wine) at a ceremony. After the
event, he suffered from insomnia and pressure of speech.
A few days later, he had grandiose ideas and announced to
run for the president of the student union. After 5 days of
sleep deprivation, he could not attend school and stayed
home to rest, reading and playing computer games some-
times. He lost his appetite, in addition to sleeplessness,
and started talking to himself, mostly about how to play
certain computer games, and talked to imaginary persons
about various plots that are not comprehensible to others,
which was indicative of auditory/visual hallucination. On
the 6th day, he went hiking and was noticed to pick up
heavy objects while hiking and made loud noises by bang-
ing them on the ground or squeezing coke bottle as if to
ease his frustration.
On hospitalization, he was screened for organic causes
and found to be negative for infection after tests with
blood and spinal fluid (antibody against N-methyl-D-as-
partate receptor (NMDAR) was also negative in spinal
fluid). No brain injury and no brain tumor were obvious
from MRI brain, X-ray and a computerized tomography
scan. His laboratory findings were mostly within normal
range. After nearly 3 weeks, his conditions stabilized
with Valproate Controlled Release 400 mg once a day
and Olanzapine 20 mg once a day, and his weight in-
creased from 51.6 kg to 59 kg half a year after medica-
tion without any increase in height (1.63 m).
However, even several months after he was discharged
from the hospital, the medication of valproate and olan-
zapine did not prevent monthly episodes of hypomania
and sleeplessness (which happened three alternate nights
every month, mostly 3 days after the full moon) that oc-
curred at monthly interval for 5 months in 2012 (From
mid-Jan to mid-May, see Fig. 2). His hypomania features
include elevated mood, participation in risky behaviors
such as making 10 km (walking or biking) trips in
deserted streets on his own without informing anyone,
going through a public park, at 3 or 4 am to school and
playing basketball with complete strangers much older
Fig. 2 Episodes of hypomania as a function of time plotted by time toaster (a freely available web tool). The time of a full moon is represented
by a filled spot while an episode of hypomania is represented with an unfilled spot, with various sizes scaled to the duration of the episodes.
Supplementation of phosphatidylcholine was initiated on May 28, 2012, and no hypomania episode was observed after that date for five months
(from mid-May to mid-Oct, 2012) and following nine months (data not shown)
Rao et al. SpringerPlus  (2015) 4:235 Page 5 of 8than himself. He also suffered from distractibility, spent
money freely and had increased goal directed activities
during his monthly cycles of hypomania.
Beneficial effect of phosphatidylcholine supplementation
for the 16-year-old Chinese boy’s hypomania symptoms
When the phosphatidylcholine supplementation was initi-
ated in mid-May, in addition to the valproate and olanza-
pine medications, after five months’ hypomania episode
(from mid-Jan till mid-May, 2012) the boy’s laboratory find-
ings were mostly normal, including hemogram, WBC dif-
ferential count, blood glucose tests, thyroid function test,
C-reactive protein, RA Factor, liver function tests, renal
function test, uric acid level, calcium, phosphate, iron levels,
tumor markers (alpha fetal protein and CEA). Although
total cholesterol, HDL, and LDL were within normal range
(4.1, 1.53 and 2.22 mmol/L respectively), the total choles-
terol/HDL ratio was slightly lower than that of the normal
range (2.7, normal range: 3.0-6.7).
In the months following the initiation of phosphatidyl-
choline supplementation, no hypomania symptoms and
insomnia were observed after the full moon, which means
that there are no nights that he cannot sleep throughout
the night and the disappearance of those hypomania fea-
tures before supplementation (Fig. 2). The boy has been
taken off all his medication after half a year of supplemen-
tation and has been symptoms free for five months (mid-
May till mid-Oct, 2012, Fig. 2) and the following nine
months (mid-Oct till mid-July, 2013, data not shown)
since he initiated the supplementation.
Association study with bipolar disorder in Chinese
The “no call” signal- rs9532989 in sequencing data and
its nearby SNPs in the same LD block with rs9532989 inthe first intron of DGKH were chosen to carry out the
association study of bipolar disorder in an age and
gender-matched Hong Kong Chinese cases and controls.
The call rate of genotyping was 100 % complete for
the bipolar disorder patients and healthy controls. There
is no difference between cases and controls group in
gender (p = 0.749) and age (p = 0.147). In allelic analyses,
we did not find any polymorphism in two SNPs –
rs17519207 (T = 1.0, C = 0.0) and rs79738935 (C = 1.0, T =
0.0), which were therefore non-informative. The sequencing
results of all samples in the remaining eight SNPs are
shown in Table 1. All the distribution of the eight SNPs in
bipolar disorder patients and healthy controls were in ac-
cordant with the Hardy-Weinberg equilibrium (P > 0.276).
In single-marker association analysis, we found that a
SNP rs77072822 was significantly associated with bipolar
disorder in allelic analyses (p = 0.011) and genotypic ana-
lyses (p = 0.003). And these associations remained signifi-
cant after 2000 permutation tests (p = 0.045 for allelic
analyses and p = 0.025 for genotypic analyses) (Table 1).
Moreover, the frequency of GC in rs77072822 was over-
represented in bipolar disorder patients comparing with the
healthy controls, which indicated that GC might be a risk
genotype to bipolar hypomania. Coincidentally, the DNA
sequence of the 16-year-old boy is the risk genotype (G/C)
in rs77072822 (Fig. 3a), whereas his healthy sister carries
the non-risk genotype (G/G) (Fig. 3b). Furthermore, associ-
ation analyses of all two-maker haplotypes containing
rs77072822 with bipolar disorder were carried out. And we
found that all of the haplotypes were significantly associated
with bipolar disorder after 2000 permutation tests (P <
0.043) (Table 2). Besides, neither rs9532988 nor rs9532989
was found to be associated with bipolar disorder in this
sample (Nominal p-value = 0.537 and 0.946, respectively)
Table 1 Single-marker analysis of eight SNPsa with bipolar disorder
Associated
allele
Frequency Allelic analyses Genotypic analyses
SNP ID Case Control P value (Nominal) P value (Perm) b P value (Nominal) P value (Perm)
rs7990452 A 0.447 0.412 0.761 - 0.956 -
rs9532987 A 0.447 0.412 0.761 - 0.956 -
rs9562372 C 0.500 0.471 0.803 - 0.388 -
rs77072822 C 0.237 0.029 0.011* 0.045* 0.003** 0.025*
rs9532988 A 0.947 0.912 0.553 - 0.537 -
rs9532989 G 0.474 0.471 0.979 - 0.946 -
rs4142112 C 0.474 0.382 0.435 - 0.700 -
rs4142111 C 0.974 0.382 0.128 - 0.347 -
aSNPs single nucleotide polymorphisms, b P value (Perm): P value after 2000 permutation tests; *P < 0.05; **P < 0.01
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SNPs were associated with bipolar disorder in a sample of
National Institute of Mental Health in Baum’s study (Fig. 1).
Discussions
In this study, we have reported on a 16-year-old Chinese
boy with bipolar hypomania symptoms who was initially
psychotic, and upon treatment with medication, responded
well and stabilized. However, he still suffered from monthly
episodes of insomnia accompanied by hypomania for
5 months despite adherence to medication. After that, he
was put on a supplement of one capsule mainly containingFig. 3 DNA sequence analyses of rs77072822 polymorphism in the 16-year
sister (b)600 mg phosphatidylcholine. In the month following
the initiation of phosphatidylcholine supplementation,
no hypomania and insomnia was observed after the full
moon and all hypomania symptoms disappeared. He
has been taken off all his medication after half a year of
supplementation and has been symptoms free for ap-
proximately one year. This finding was consistent with
Chen’s report, in which they found that the choline
level, considered as sex-specific urinary metabolite bio-
markers for diagnosing male and female bipolar disorder
patients, was decreased in bipolar disorder male subjects
(Chen et al. 2014). The decline of phosphatidylcholine-old boy with bipolar hypomania (a) and his 19-year-old healthy
Table 2 Association analyses between two-marker models with
rs77072822 and bipolar disorder
Frequency P valuea
Block Haplotype Case Control (Perm)
rs77072822-rs7990452 C-T 0.237 0.029 0.038*
rs77072822-rs9532987 C-G 0.237 0.029 0.034*
rs77072822-rs9562372 C-C 0.237 0.029 0.043*
rs77072822-rs9532988 C-A 0.237 0.029 0.012*
rs77072822-rs9532989 C-T 0.237 0.029 0.019*
rs77072822-rs4142112 C-G 0.237 0.029 0.036*
rs77072822-rs4142111 C-C 0.237 0.029 0.012*
aP value (Perm): P value after 2000 permutation tests, *p < 0.05
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and PA, in which DGK enzymes phosphorylate DAG into
PA when receptors in phosphoinositide pathway receiving
activation. This hypothesis suggested that DGK enzymes
are likely to play a vital role in the pathogenesis of bipolar
hypomania symptoms.
Diacylglycerol kinase eta (DGKH), encoding an import-
ant member of DGK enzymes family, has been reported
associating with bipolar disorder in a genome-wide associ-
ation study (GWAS) and replicated in Chinese Han popu-
lation (Baum et al. 2008; Zeng et al. 2011). Meta-analyses
in metamoodics database also compiled results of several
GWAS studies and confirmed the association of DGK en-
zymes with bipolar disorder. Moreover, the role of DGKH
in mental disorder was further confirmed from data ob-
tained in animal studies. Mapping of different strains of
mice found that a region in chromosome 14 (which con-
tains DGKH) is associated with the midsagittal area of the
corpus callosum (MSACC), which has been associated
with a number of cognitive and behavioral phenotypes, in-
cluding bipolar disorder, obsessive-compulsive disorders,
psychopathy, suicidal tendencies, schizophrenia, autism,
and attention deficit hyperactivity disorder (Newbury and
Rosen 2012).
In this study, for the first time the association analysis
showed that GC in rs77072822 is over-represented in bi-
polar disorder patients indicating that GC might be a
risk genotype to bipolar hypomania. Thus, we assume
that the missed call of the boy different from his three
family members in rs9532989 might be due to the muta-
tion in rs77072822 as these two polymorphisms have a
very close physical position in chromosome and are lo-
cate in the same linkage disequilibrium block (Fig. 1).
This SNP marker that we found to be associated with
bipolar disorder is a novel marker that has not been re-
ported in previous studies, although it is located in the
same region, i.e. the first intron of DGKH, which was
mostly reported to be associated with bipolar disorder
(Baum et al. 2008; Zeng et al. 2011). Such differences in
marker SNP between our study and the previous studiescould be due to differences in the risk mutation located
in a same LD block for the different populations, or that
the risk allele arose separately on different genetic back-
ground in different regions. In addition, we found that
the 16-year-old boy carries the risk genotype (G/C) in
rs77072822, whereas his 19-year-old healthy sister has
the non-risk genotype (G/G). Together, these findings
could provide a possible explanation at the genetic level
why the 16-year-old boy responded well to supplementa-
tion of phosphatidylcholine. However, this possible hy-
pothesis should be supported by more evidence at either
the mRNA or the protein level.
One limitation of our study is that the effect could be
compounded by the presence of vitamin B complex in
the supplement; however, earlier supplementation of
vitamin B complex did not alleviate his hypomania and
insomnia. Further double blind, randomized, placebo-
controlled clinical trials should be carried out to test the
hypothesis that subjects with the risk genotype of DGKH
respond better to phosphatidylcholine supplementation
than those observed with the non-risk genotype. In
addition, the small sample size of association study
might affect the validity of significant association, which
suggests that the data in this study should be interpreted
with caution; nevertheless, the association of rs77072822
with bipolar disorder remained significant after 2000
permutation tests. Although we reported that the hypo-
manic symptoms and the insomnia were observed after
the full moon, not much is known about the scientific
meaning of this association despite extensive searching
of the literature, thus it is likely that the timing of the
episode after the full moon is merely a chance event, i.e.
the hypomanic episode occurred regularly in this case
and it just happened to fall after the full moon.
In summary, the 16-year-old boy appears to have bene-
fited from the supplementation with phosphatidylcholine
and recovered from hypomania symptoms. He carries a
risk genotype (G/C) in rs77072822 which lies in the first
intron of DGKH gene that was mostly reported to be asso-
ciated with bipolar disorder. Thus, this finding is consistent
with the hypothesis that alleviating the phosphatidylcholine
deficiencies might accompany with the risk variant of
DGKH, Personalized genomics might improve the effica-
cies of such supplementation and help in the design of
new treatment strategies for bipolar disorder.
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